RecruitingPsoriasis (PsO)
A Phase 2 Study of HB0017 in Psoriasis Patients
Eligible age
18–75 yrs
Accepts
All genders
Locations
0 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects
Sponsor: Huabo Biopharm Co., Ltd.
You may qualify if…
- ✓ Male or female subjects aged 18-75 years (inclusive)
- ✓ Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization.
- ✓ Psoriasis Area Severity Index (PASI) \>=12 and body surface area (BSA) affected by PSO \>=10% and Static Physician Global Assessment (sPGA) score \>=3.
- ✓ Subjects who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator
- ✓ Subjects who are able to use effective contraception from the screening period to 6 months after the last dose
You may not qualify if…
- ✕ Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline Drug-induced psoriasis
- ✕ Ongoing use of prohibited treatments
- ✕ Any active infection (other than common cold) within 14 days
- ✕ Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization
- ✕ Have previously received any drug that directly targets IL-17 or IL-17 receptor
- ✕ Have concurrent or recent use of any biologic agent within the following washout periods: etanercept \<28 days; infliximab and adalimumab \<60 days; golimumab \< 90 days; anti-IL-12/anti-IL-23 or anti-IL-23p19 antibody drugs \<6 months; or other anti-psoriatic therapy not listed herein within its 5 half-lives prior to randomization
- ✕ A history of inflammatory bowel disease or other serious autoimmune disease
- ✕ Previously diagnosed with serious mental illness such as anxiety, depression or suicidal tendency
Source: ClinicalTrials.gov · NCT06592274 · last updated 2025-09-15